International Advertising and marketing Useful resource Administration Market By Part, By Deployment Sort, By Enterprise Measurement, By Finish Person, By Area, Trade Evaluation and Forecast, 2020

Globe Newswire

Global Biodefense Market by Product, Region, Industry Analysis and Forecast, 2020-2026

The size of the global Biodefense market is expected to reach $ 17. 5 billion by 2026, which corresponds to a market growth of 5.8% CAGR over the forecast period. Biodefense refers to a group of medical or military steps taken as a result of restoring a nation’s biosecurity. New York, February 10, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces Publication of Global Report Biodefense Market By Product, Region, Industry Analysis, And Forecast, 2020-2026 “- https: //www.reportlinker. com / p06021879 /? utm_source = GNW Threats such as biological toxins or infectious agents can be used with malicious intent such as killing or infecting humans, animals or the environment and provoking biological warfare. There are several agents used for bio-terrorism, such as living organisms such as bacteria, viruses, fungi and toxins. In order to create social and economic turmoil, these agents can be targeted to infect and kill people. The biological defense market is being driven by various factors such as beneficial government initiatives, increased government attention and Funding driven by biological defense strategies Furthermore, increasing investments by private companies and the increasing spread of various active substances such as influenza, Ebola virus and Zika virus will increase the market for biological defense in the coming years. In recent years, genetic engineering and biotechnology have seen massive technological advances that offer innovative ways to combat these deadly and naturally occurring viruses that can be redesigned to cause additional damage. There is also the ready availability of these organisms, which makes biological defense an important issue for countries around the world. Various biological agents such as botulism, anthrax, as well as chemical and nuclear agents that cause severe destruction have been used to carry out bio-terrorism. By Product-Based, the market is divided into Anthrax, Smallpox, Botulism, Radiation / Nuclear and Other Products. The anthrax segment acquired the highest market share in 2019. The segment is expected to have a significant CAGR over the forecast years. Anthrax is caused by Bacillus anthracis, a gram-positive bacterium that is one of the most preferred weapons against bioterrorism. These spores are widely preferred because they can be easily transmitted into the environment by adding them to foods, water, powders, and sprays. By Regions On the basis of the regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America (Central America) East Africa. North America had the highest revenue share in the biological defense market in 2019. The region is also expected to have a significant CAGR in the forecast years due to advances in technology, the presence of massive federal investment, and increasing awareness among the population. In addition, the presence of the leading players in this region is a positive factor for the market forecast. The market research report covers the analysis of key market players. Key companies featured in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd. , Cleveland BioLabs, Inc., Bayern Nordic A / S and Alnylam Pharmaceuticals, Inc. Strategies for the Biodefense Market Jul-2020: Altimmune entered into a collaboration with DynPort Vaccine Company, a general dynamic information technology company. In that collaboration, they aimed to coordinate with U.S. government funding efforts and provide program management, regulatory support for AdCOVID, integration of drug development activities, and Altimmunes single-dose intranasal COVID-19 vaccine candidates. June 2020: SIGA Technologies announced the supply of oral drugs TPOXX to the US Department of Health. June 2020: Ichor Medical Systems signed an agreement with Immunomic Therapeutics, a private clinical-stage biotechnology company. This agreement was aimed at supporting the development of ITI vaccine therapy for plasmid DNA vaccines ITI-1001. April 2020: Emergent BioSolutions signed a partnership agreement with the US government. The partnership focused on accelerating the development of a plasma-derived therapy for patients with COVID-19. Emergent received $ 14.5 million from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the US Department of Health’s Deputy Secretary for Preparedness and Response (ASPR), to resolve COVID-HIG program, one of two hyperimmune development programs announced by Emergent.Mar-2020: SIGA Technologies has partnered with Turnstone Biologics, a privately held immuno-oncology company. The collaboration was aimed at providing TPOXX in conjunction with Turnstone’s proprietary platform for oncolytic immunotherapy with SKV vaccinia. The platform uses vaccinia viruses, designed for enhanced selectivity and safety, as well as highly effective immune stimulation, and offers multiple therapeutics delivery directly to tumors. The collaboration also provides Turnstone with access to SIGA’s TPOXX oral antiviral capsules for use in future clinical programs. September 2019: Bavarian Nordic received JYNNEOS and Monkeypox Vaccine approval from the US Food and Drug Administration (FDA). JYNNEOS prevents smallpox and monkey pox in adults and the elderly who are at high risk of smallpox or monkey pox infections. It is the only approved non-replicating smallpox vaccine in the US and the only approved Monkeypox vaccine worldwide. September 2019: Emergent BioSolutions received $ 20 million to develop and manufacture an auto-injector including diazepam to cure seizures caused by nerve agents, U.S. Department of Defense. Emergent’s device was targeted at intramuscular buddy administration for use in military environments and civil emergencies. July 2019: Altimmune acquired Spitfire Pharma, a California drug developer. As part of the acquisition, Spitfire became Spitfire’s flagship treatment for non-alcoholic steatohepatitis (NASH), a condition characterized by fat accumulation in the liver and integrated into Altimmune’s pipeline for flu and anthrax vaccines. July 2019: SIGA Technologies signed a multi-year contract with the United States Department of Defense (DoD). The contract was aimed to support the work needed to achieve a potential label extension for TPOXX, including post-exposure prophylaxis (PEP) of smallpox. March 2019: Ichor Medical Systems partnered with AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company. The collaboration focused on the development and clinical evaluation of plasmid DNA constructs. In addition, Ichor received upfront and annual payments, as well as development milestones. September 2018: SIGA Technologies entered into a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services of the Assistant Secretary for Preparedness and Response. The contract was aimed at delivering oral and intravenous formulations of TPOXX to the Strategic National Stockpile. August 2018: Cleveland BioLabs formed a 50:50 joint venture called Genome Protection, Inc. (GPI). This joint venture is the result of an agreement between Cleveland BioLabs and Everon BioSciences, Inc. (Everon). GPIs aim to develop and commercialize drugs for anti-aging applications that can extend human health and lifespan. GPI also announced an agreement for Future Equity (SAFE) with the venture capital fund Norma Investments Limited (Norma). Under the SAFE, GPI granted Norma the right to purchase shares in GPI’s share capital for payment of up to $ 30 million, of which $ 10.5 million was paid shortly after the execution of the SAFE. July 2018: SIGA Technologies announced that its Oral TPOXX has received approval from the U.S. Food and Drug Administration (FDA), which treats smallpox to mitigate the effects of a possible outbreak. October 2017: Emergent BioSolutions acquired Sanofi’s ACAM2000 business, which includes ACAM2000, the only smallpox-approved vaccine in the US Food and Drug Administration. As part of this acquisition, Emergent wanted to take responsibility for its existing contract with the Centers for Disease Control and Prevention (CDC) and offer ACAM2000 for the Strategic National Stockpile (SNS). September 2017: Bavarian Nordic signed a contract with Biomedical Advanced Research and Development Agency (BARDA). The contract focused on delivering its freeze-dried Imvamune smallpox vaccine to the US Strategic National Stockpile. July 2017: Emergent BioSolutions signed an agreement with GSK, a leading healthcare company. The agreement was aimed at acquiring raxibacumab, a fully human monoclonal antibody approved by the US Food and Drug Administration (FDA) for the cure and prevention of inhaled anthrax. The acquisition strengthened its leading position in the market and expanded the franchise in Vaccines and Therapeutics against Bioterrorism Threats Category A. Scope of StudyMarket Segmentation: By Product • Anthrax • Smallpox • Botulism • Radiation / Nuclear Technology, • Other Products By Geography • North America USA Canadao Mexicoo Rest of North America • Europeo Deutschlando UKo Franceo Russiao Spaino Italyo Rest of Europe • Asia-Pacifico Chinao Japano Indiao South Koreao Singapuro Malaysiao Rest of Asia-Pacific • LAMEAo Brazilo Argentinao UAEo Saudi Arabieno South Africao Nigeriao Rest of LAMEACompanies Profiled • Xoma Corporation • Altimmune, Inc. • Emergent BioSolutions, Inc. • Dynavax Technologies Corporation • SIGA Technologies, Inc. • Elusys Therapeutics, Inc. • Ichor Holdings, Ltd. • Cleveland BioLabs, Inc. • Bavarian Nordic A / S • Alnylam Pharmaceuticals, Inc. Unique Offers • Comprehensive Coverage • Highest number of market tables and maps • Subscription-based model available • Best price guaranteed • Assured support for post-sales research with 10 % Freedom to Customize Read the full report: https://www.reportlinker.com/p06021879/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need in one place, instantly. __________________________ CONTACT: Clare: cl[email protected] USA: (339) -368-6001 Intl: +1 339-368 -6001